TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05532839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: The therapy lasted 6 weeks, and HIIT comprised of two 12-24 × 30 second high-intensity runs separated by thirty seconds of relaxation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training
Description: The MICT ran continuously for 24-48 minutes. From the day of the six weeks intervention strategies, the mentioned assays were conducted: Yo-Yo Intermittent Recovery Test level 1, repeated sprint ability , sprint test, alter of way test which is t drill, and physical activity enjoyment scale and shuttle run. Through these trainings, individuals in both groups must follow the old their balanced meal.
Study: NCT06001476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: For eligible patients, use cold snare polypectomy to resect 5-9mm short-pedicled, broad-pedicled or sessile small bowel polyps
Study: NCT05673512

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Injection of IAH0968 + CAPEOX
Description: PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PLACEBO+CAPEOX
Description: PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
Study: NCT05330182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMN-201
Description: LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMN-201
Description: LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.
Study: NCT05445843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: JDQ443 orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: JDQ443 orally administered
Study: NCT06118034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Take 0.5mg of colchicine tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 0.5mg of starch tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
Study: NCT05386563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)
Description: taVNS will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (cymba concha, earlobe, and ulnar side of the wrist). Stimulation is delivered by a 3000ms pulse train (100us pulse width and 25Hz stimulation frequency). The current applied will be between 0.01uA to 9uA. The intervention will be delivered over the course of four sessions approximately one week apart.
Study: NCT05010031

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Description: An initial cohort of 12 evaluable patients will be treated with 4Gyx2, with adaptive dosing planned for expansion cohorts pending the number of failures observed after 6 month observation of the initial cohort.
Study: NCT05386563

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham stimulation will be delivered by Digitimer DS7 Constant Current Stimulator (an FDA cleared medical device intended for human nerve and muscle stimulation).~Stimulation is delivered via sticky pad electrodes all placed on the left side of the body (either earlobe or forearm).
Study: NCT05471037

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long Biliopancreatic Limb LRYGB
Description: LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short Biliopancreatic Limb LRYGB
Description: Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
Study: NCT06393517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 IR (Formulation 1)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 IR (Formulation 1)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 IR (Formulation 1)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 IR (Formulation 1)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 2)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 2)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 2)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 2)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
Study: NCT04328584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical navigation system
Description: Navigation system providing surgeons with an additional view of the chest wall lesion
Study: NCT04485611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised aerobic + resistance training and nutritional support
Description: The intervention will consist of individualized exercise training delivered remotely using VA telehealth technology, combined with nutritional support consisting of tailored nutritional advice, protein supplementation, multivitamin and vitamin D supplements\]\]. Adherence to the intervention will be enhanced by use of automated text messages and monitored using activity trackers.
Study: NCT05409456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mild aerobic exercise
Description: mild aerobic exercise given to group A on treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate aerobic exercise
Description: moderate aerobic exercise given to group B on treadmill
Study: NCT05838781

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Risk prediction model
Description: A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Risk prediction model
Description: A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 14-days continuous ECG monitoring
Description: 14-days continuous ECG monitoring with an ECG patch.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 14-days continuous ECG monitoring
Description: 14-days continuous ECG monitoring with an ECG patch.
Study: NCT05903222

Intervention type: OTHER
Intervention: Non-Interventional
Description: This study is a non-interventional study of all patients previously enrolled in the PALACS trial
Study: NCT05064709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System
Description: The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: OPTIMIZER™ Smart Mini System
Description: The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.
Study: NCT06110689

Intervention type: OTHER
Intervention: VU-AMS device
Description: Patients will wear the VU-AMS monitor prior to MRI.
Study: NCT06393517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 2)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 2)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
Study: NCT06455059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide
Description: Subcutaneous injection of recommended dose of vosoritide based on weight-band dosing once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of recommended dose of placebo
Study: NCT04975685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: SMART (Strengthening Mental Abilities Through Relational Training) is a web-based cognitive training program that directly trains 'relational skills' - skills necessary to understand how concepts relate to one another, which underpin complex cognition.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham brain training (Sudoku)
Description: Sudoku was selected to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials.
Study: NCT05335187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micro-macro electrode implantation
Description: One or a handful of micro-macro electrodes are implanted for 2-4 weeks in patients undergoing epilepsy monitoring with intracranial EEG electrodes.
Study: NCT06384040

Intervention type: PROCEDURE
Intervention: platelet-rich plasma knee injection
Description: platelet-rich plasma knee injection and observation for 12 months for definition of responder and non responder

Intervention type: PROCEDURE
Intervention: platelet-rich plasma knee injection
Description: platelet-rich plasma knee injection and observation for 12 months for definition of responder and non responder
Study: NCT05377385

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about usability of the Omnipod DASH insulin administration system
Study: NCT05130814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue light photobiomodulation
Description: 1 minute irradiation of blue light performed with EmoLED device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cleansing
Description: cleaning of the wound area with saline or ringer's lactate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleansing
Description: cleaning of the wound area with saline or ringer's lactate

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid gauze plus polyurethane foam
Description: every 48 hours or as needed

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: hyaluronic acid gauze plus polyurethane foam
Description: every 48 hours or as needed
Study: NCT05923931

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cooling blanket
Description: On the basis of the cooling methods of non-cooling blanket group, combine the cooling blanket to cool down. The cooling blanket is required to be activated within 30min after admission. The blanket temperature will be set at 4-10℃, and the target body temperature is 38℃.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-cooling blanket
Description: Patients do not receive cooling blanket according to randomization. Cooling body temperature by: control the temperature of the emergency room to 20-24℃, 4℃ fluid infusion, ice packs, evaporation, convection,etc.
Study: NCT06464380

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saffranal
Description: HCC patients will receive 50 mg safranal regimen in dose of once per day for six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HCC patients will receive Placebo in dose of once per day for six months.
Study: NCT05873153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Education materials on high blood pressure, lowering sodium, starting an exercise program, and weight management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitor
Description: Blood pressure cuff for home use
Study: NCT06303440

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Physical Therapy+ Balance Training
Description: Each session will be begun with routine PT treatment and lasted for 45 minutes in total. To start, the participants will be asked to do warm-up exercises, sitting comfortably on a chair with their backs and feet well supported, the participants will be instructed to breathe in and out. Warm-up exercises will be carried out for 5 minutes. Stretching exercises will be performed for 15 minutes per session, and stretches were held for 30 seconds with four repetitions of each of the following areas, shoulder flexors, elbow and wrist flexors, hip flexors, hip adductors, knee flexors, and calf, 10 seconds of rest period will be added after stretching of one muscle group. Participants will have a 15 minutes session of exercises neck holding on form roller for 1 minute with two repetitions, astride-sitting on foam roller for 2 minutes with four repetitions, weight on both hands on gym ball for 1 minute with two repetitions and hip adductors strengthening for 1 minute with three repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality+ Routine Physical Therapy
Description: The exercises will be selected, and the difficulty level will be gradually increased according to participant's performance. Starting from the penguin slide, they will progress to table tilt. Initially, each game will be played for 2 minutes per session. With the progression of performance, 4 minutes of table tilt will be added. While playing this game, a typical mobility pattern will be initiated, and balance will be improved. In the same week, the subjects performed single-leg extensions for 1 minutes. In the following weeks, Balance Bubble, Advanced step, and Basic Run will be added to the plan. The participants will perform these activities for 7 minutes per session. Treatment sessions then progressed to motor function games, including bowling, tennis, kicking, and boxing (least challenging to most challenging), with most treatment sessions ending with boxing will be provided for 7 minutes and routine physical therapy for 30 minutes as explained in control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery+ Routine Physical Therapy
Description: The 15 minutes of Motor Imagery session will be provided to participants. It's a three step process that will be used to incorporate the technique.~Step I, The self-recorded videos of the principal researcher performing a normal movements will be shown to participant.~Step II, The participants will be asked to imagine movement with eyes closed, and breathe deeply.~Step III The participants will be asked to perform the movement you watched in video and routine physical therapy of 30 minutes will be provided.~During the presentation of a video clip, patients will watch the video and afterwards try to do movement as same as shown in video.
Study: NCT06115486

Intervention type: OTHER
Group type: OTHER
Intervention: Control Arm ACSM Guidelines
Description: The control group will follow resistance training guidelines from the American College of Sports Medicine. Eight to ten multi-joint exercises will be performed to stress the major muscle groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Arm 6-12-25 repetitions per set
Description: The exercise regimens will employ a mixture of compound exercises utilizing both open and closed kinetic chain movements (CKC), focusing on exercises with the goal of increasing skeletal muscle mass and body composition. The regimen will incorporate 6, then 12, then 25 repetitions in sequence per set per muscle group with minimal amounts of rest between.
Study: NCT05909410

Intervention type: OTHER
Intervention: Survey investigating the CHC use and patients' perception about the relationship between CHC and cancer, diseases and symptoms
Description: This survey investigated the CHC use (type and timing of administration) and patients' perception about the relationship between CHC and cancer, diseases and symptoms

Intervention type: OTHER
Intervention: Survey investigating the CHC use and patients' perception about the relationship between CHC and cancer, diseases and symptoms
Description: This survey investigated the CHC use (type and timing of administration) and patients' perception about the relationship between CHC and cancer, diseases and symptoms
Study: NCT06393517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 3)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 3)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
Study: NCT05130814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zinc cream or hyaluronic acid sodium salt + metallic silver
Description: applied to prevent and/or treat the skin maceration of the surrounding area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zinc cream or hyaluronic acid sodium salt + metallic silver
Description: applied to prevent and/or treat the skin maceration of the surrounding area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: topical treatment
Description: topical treatment indicated for that stage of the lesion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: topical treatment
Description: topical treatment indicated for that stage of the lesion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bandage
Description: it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bandage
Description: it consists of a polyurethane film -thin hydrocolloid plate or a pressure discharge system made with hydrocolloids and polyurethane foam, known as pressure relief system
Study: NCT06299111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN9933
Description: Intravenous (IV) single dose administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7508
Description: IV single dose administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV single dose administered
Study: NCT05431114

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Images of the injured shoulder will then be taken with magnetic resonance (MR) scanner. MRIs of each participant's shoulder will be acquired before and after completion of an exercise protocol.
Study: NCT06274944

Intervention type: DEVICE
Intervention: nasogastric tube placement pH confirmation device
Description: Each participation will get the contents tested by the novel device and the standard of care procedure.
Study: NCT05789173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone and Tizanidine
Description: Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth at baseline (control)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz, Methadone and Tizanidine
Description: Each CYP2B6 genotype predicted phenotypes will receive methadone (10 mg) and tizanidine (4 mg) by mouth after pretreatment with efavirenz (600 mg PO for 16 days)
Study: NCT05395871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Message
Description: Messaging involving increased salience, increasing positive emotions and information on health consequences

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Message + Video
Description: Messaging as above. The video also includes information on emotional consequences, problem solving, anticipated regret, reducing negative emotions and credible source techniques.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Message
Description: Standard usual care message involving link to non-behavioural science informed video
Study: NCT05675865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoablation procedure
Description: ablation procedure for VT using the investigational device
Study: NCT04538378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablet will be administered at a total daily dose of 600 mg orally in two divided doses, approximately 12 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be administered intravenous (IV) into a peripheral or central vein on Day 1 of every cycle at a flat dose of 1,500 mg.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EKG
Description: Screening and all cycles Day 1 and Day 15 (+/- 3) days. One cycle is 28 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: Baseline and all cycles Day 15 (+/- 3) days. One cycle is 28 days.